Understanding Your Hereditary Cancer Risk Is the First Step Toward Protecting Your Future and the Future of Your Loved Ones.
Empower™, developed by Natera, is a comprehensive germline genetic test that evaluates genetic alterations associated with hereditary cancer syndromes. The analysis is performed using a blood sample at Natera’s laboratory in the United States, helping assess an individual’s hereditary cancer risk and supporting the planning of early detection, screening, and risk management strategies.
Empower™ is used not only for hereditary cancer risk assessment but also to help identify inherited biomarkers that may influence treatment decisions in individuals diagnosed with cancer. In particular, alterations detected in BRCA1, BRCA2, and genes associated with Lynch syndrome may support the evaluation of targeted treatment options.
Identifying genetic variants associated with hereditary cancers enables risk assessment for both individuals and their family members. To provide a more comprehensive molecular profile, Empower™ can also be used alongside somatic genomic profiling tests such as FOCUS CGP veya Altera™ .
Cancer Types:
Breast, Ovarian, Endometrial (Uterine), Colorectal, Gastric, Prostate, Pancreatic, and Melanoma.
| Feature | Details |
|---|---|
Who Should Be Tested? |
|
Cancer Type | Hereditary Cancers |
| Sample Type | Blood (EDTA Tube) |
| Method | Next-Generation Sequencing (NGS) |
| Coverage | 81 Genes |
| Turnaround Time (TAT) | 2–3 Weeks |
* Genetic counseling is included as part of this test.
** BRCA1/2 MLPA analysis and the Lynch syndrome panel are included in this test.
*** The panel content can be customized based on clinical findings, family history, and genetic counseling. A detailed gene list is available upon request.
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
